Clinical and Paraclinical Characteristics of Severe Bronchiolitis in Children From 2 Months to 12 Months at the Children's Hospital 1 in Ho Chi Minh City - Vietnam

• Conditions: Epidemiological, Clinical, Paraclinical Characterictics of Severe Bronchiolitis

• Registration Number: NCT04174430
• Lead Sponsor: University of Medicine and Pharmacy at Ho Chi Minh City

Brief Summary

Goal: The aim of this study is to determine the epidemiological, clinical, paraclinical characteristics and treatment of severe bronchiolitis at the Children Hospital N01 in 2001-2002.

Materials and method: in this cross-sectional study, specimens of 51 patients with severe bronchiolitis at the Children Hospital N01 from March, 1 st 2001 to February, 28th 2002 are described and analyzed.

Detailed Description

Not available

Study Timeline

• Study Start: 2017-08-01
• Status Verified: 2019-11
• Study First Submitted: 2019-11-16
• Study First Submitted QC: 2019-11-21
• Last Update Submitted: 2019-11-21
• Study First Posted: 2019-11-22
• Last Update Posted: 2019-11-25
• Primary Completion: 2019-12-01
• Study Completion: 2019-12-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 51

Inclusion Criteria

• children younger from 2-12 months present fever (usually ≤38.3ºC [101ºF]) ,cough, and respiratory distress (eg, increased respiratory rate, retractions, wheezing, crackles)
• preceded by a one- to three-day history of upper respiratory tract symptoms (eg, nasal congestion and/or discharge) ]
• Respiratory distress.

Exclusion Criteria

• refusal to give informed consent
• mucus sample Barlett <=0

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Number of participants with Severe bronchiolitis at the Children Hospital N01	2 years	Bronchiolitis in infants with: * Preterm birth : gestational age \< 37 weeks; * Respiratory failure: * Irritable condition; * Breath rate \> 50 per minute; * Hypoxiemia: SpO2 \< 94%; * Poor feeding; * Hemodynamically significant congenital heart disease (congennital heart failure, moderate to severe pulmonary hypertension or cyanotic heart disease)

Trial Locations

Locations (1)

Respiratory; 🇻🇳 Ho Chi Minh City, District 10, Vietnam